GT201000140A - Tratamiento de cáncer de mama con un inhibidor de parp solo o en combinación con agentes anti-tumorales. - Google Patents

Tratamiento de cáncer de mama con un inhibidor de parp solo o en combinación con agentes anti-tumorales.

Info

Publication number
GT201000140A
GT201000140A GT201000140A GT201000140A GT201000140A GT 201000140 A GT201000140 A GT 201000140A GT 201000140 A GT201000140 A GT 201000140A GT 201000140 A GT201000140 A GT 201000140A GT 201000140 A GT201000140 A GT 201000140A
Authority
GT
Guatemala
Prior art keywords
treatment
breast cancer
parp inhibitor
combination
tumor agents
Prior art date
Application number
GT201000140A
Other languages
English (en)
Inventor
Barry M Sherman
Bradley Charles
Valeria S Ossovskaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000140A publication Critical patent/GT201000140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A TRATAMIENTO DE CÁNCER DE MAMA CON UN INHIBIDOR DE PARP EN EL QUE OTRAS TERAPIAS HAN FALLADO CONSIDERANDO QUE SON CÁNCERES DE MAMA QUE SON RECEPTORES HORMONALES NEGATIVOS (HR NEGATIVOS) Y POR LO TANTO SE HAN INTENTADO OTRAS QUIMIOTERAPIAS ADYUVANTES.
GT201000140A 2007-11-12 2010-05-11 Tratamiento de cáncer de mama con un inhibidor de parp solo o en combinación con agentes anti-tumorales. GT201000140A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98733307P 2007-11-12 2007-11-12
US1236407P 2007-12-07 2007-12-07
US5852808P 2008-06-03 2008-06-03

Publications (1)

Publication Number Publication Date
GT201000140A true GT201000140A (es) 2012-04-23

Family

ID=40639414

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000140A GT201000140A (es) 2007-11-12 2010-05-11 Tratamiento de cáncer de mama con un inhibidor de parp solo o en combinación con agentes anti-tumorales.

Country Status (23)

Country Link
US (3) US7732491B2 (es)
EP (1) EP2217227B1 (es)
JP (1) JP2011503111A (es)
KR (1) KR20100102609A (es)
CN (2) CN103169973A (es)
AR (1) AR069291A1 (es)
AU (1) AU2008321128A1 (es)
CA (1) CA2705537A1 (es)
CO (1) CO6290650A2 (es)
CR (1) CR11485A (es)
DO (2) DOP2010000141A (es)
EC (1) ECSP10010240A (es)
GT (1) GT201000140A (es)
IL (1) IL205689A0 (es)
MA (1) MA31909B1 (es)
MX (1) MX2010005222A (es)
NI (1) NI201000083A (es)
NZ (1) NZ586125A (es)
RU (2) RU2480211C2 (es)
SG (1) SG185952A1 (es)
TN (1) TN2010000208A1 (es)
TW (2) TW201249430A (es)
WO (1) WO2009064738A2 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
ES2609931T3 (es) * 2010-06-18 2017-04-25 Myriad Genetics, Inc. Métodos y materiales para evaluar la pérdida de heterocigosidad
EP2595618A1 (en) * 2010-07-19 2013-05-29 BiPar Sciences, Inc. Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
US20140315973A1 (en) * 2010-10-07 2014-10-23 Agency For Science, Technology And Research Parp-1 inhibitors
CN103221384B (zh) 2010-11-05 2015-05-13 浙江海正药业股份有限公司 具有抗癌活性的苯甲酰胺衍生物及其制备方法和用途
WO2012106559A1 (en) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012155063A1 (en) * 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
EP2717911A1 (en) * 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
EP3693473A1 (en) 2011-06-17 2020-08-12 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
US20130045162A1 (en) * 2011-08-15 2013-02-21 Morehouse School Of Medicine Delivery system for specifically targeting cancer cells and method of use thereof
FI20115876A0 (fi) * 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
KR20140069271A (ko) * 2011-09-26 2014-06-09 셀진 코포레이션 화학요법 내성 암에 대한 병용 요법
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
FI2794907T4 (fi) 2011-12-21 2023-03-27 Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi
US8889707B2 (en) * 2012-02-08 2014-11-18 Malka COHEN-ARMON Treatment of addiction
NZ628813A (en) 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
BR112014029954A2 (pt) * 2012-06-01 2017-06-27 Berg Llc tratamento de tumores sólidos usando coenzima q10
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
WO2014150840A1 (en) * 2013-03-15 2014-09-25 Medimmune, Llc Methods of treating breast cancer
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
ES2853973T3 (es) * 2013-04-09 2021-09-20 The Board Of Trustees Of The Univ Of Illionis Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
AU2015206667B2 (en) * 2014-01-14 2020-05-14 Nektar Therapeutics Combination-based treatment method
PT3104939T (pt) 2014-02-10 2024-07-17 Fred Hutchinson Cancer Center Tratamento de ataque cardíaco e lesão isquémica com iodeto de sódio
EP3137076A4 (en) * 2014-05-02 2017-12-06 Emory University Selective chemotherapy treatments and diagnostic methods related thereto
US9303069B2 (en) * 2014-05-05 2016-04-05 University Of Mississippi Medical Center Peptides for treating cancer
CA2958801A1 (en) 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
US10196693B2 (en) * 2014-12-12 2019-02-05 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
CN114927178A (zh) * 2015-06-12 2022-08-19 格尼亚Ip控股私人有限公司 患者和生物样本识别和追踪的方法和系统
EP3373967B9 (en) * 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
EP3440052B1 (en) * 2016-04-06 2023-10-25 University Of Oulu Compounds for use in the treatment of cancer
GB201607629D0 (en) 2016-05-01 2016-06-15 Genome Res Ltd Mutational signatures in cancer
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
MX2019011543A (es) 2017-03-31 2019-12-16 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
MA48637A (fr) * 2017-05-09 2021-03-17 Merck Sharp & Dohme Polythérapies pour le traitement du cancer
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
WO2019051025A2 (en) * 2017-09-06 2019-03-14 The Trustees Of Columbia University In The City Of New York TREATMENT OF AGGRESSIVE CANCERS BY TARGETING C9ORF72
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
WO2019099736A1 (en) * 2017-11-15 2019-05-23 The Regents Of The University Of California Methods of treating extrachromosomal dna expressing cancers
SG11202007535VA (en) * 2018-02-12 2020-09-29 Cinda Pharma Ab Thioredoxin reductase inhibitors for use in the treatment of cancer
US10953209B2 (en) * 2018-03-28 2021-03-23 Board Of Regents Of The University Of Texas System Treating tumors using TTFields combined with a PARP inhibitor
BR112020023136A2 (pt) * 2018-05-14 2021-02-09 Nuvation Bio Inc. compostos de alvo de receptor de hormônio nuclear anticâncer
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
AU2020226863B2 (en) 2019-02-22 2023-04-06 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
WO2020232133A1 (en) * 2019-05-14 2020-11-19 Georgetown University Methods of treating gastrointestinal cancers and tumors thereof using combination therapy
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
JP2023500702A (ja) * 2019-11-04 2023-01-10 ファラデイ ファーマシューティカルズ， インコーポレイテッド 化学療法に関連した悪液質および心毒性の治療ならびに予防のためのヨウ化化合物の使用
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN115175899A (zh) * 2019-12-31 2022-10-11 金耐特生物制药公司 使用cdk12/13抑制剂治疗癌症
CN111362828A (zh) * 2020-03-30 2020-07-03 山西医科大学 一种18f标记的氟丙酰化鸟氨酸及其制备方法和应用
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
US12005092B2 (en) * 2021-12-22 2024-06-11 Laura Mann Kevehazi Herbal composition for breast cancer prevention
WO2024016014A2 (en) * 2022-07-15 2024-01-18 Lantern Pharma Inc. Method for treating breast cancers and parp resistant breast cancers

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2669583A (en) * 1954-02-16 X-amroo-zralkoxbbenzamdjes
WO1997004771A1 (en) 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
US2006735A (en) * 1932-11-17 1935-07-02 Gen Aniline Works Inc Nitro-aryl amino-aryl amines
NL247377A (es) * 1957-11-25
US3161564A (en) 1960-10-03 1964-12-15 Salsbury S Lab Dr Veterinary composition containing halo-nitro-benzamides and methods of using same
US3228833A (en) * 1962-12-17 1966-01-11 Sterling Drug Inc Anticoccidial compositions and methods of using same
AR204004A1 (es) 1973-04-02 1975-11-12 Lilly Co Eli Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina
FR2456731A1 (fr) 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
ATE107705T1 (de) * 1986-01-17 1994-07-15 Ronald W Pero Test zur feststellung der empfänglichkeit für dns-assoziierte krankheiten.
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0494231A4 (en) 1989-09-26 1992-09-16 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5719151A (en) * 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
ES2137932T3 (es) * 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5191082A (en) * 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) * 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
EP0533902A1 (en) 1991-04-10 1993-03-31 Octamer, Inc. A method for inhibition of retroviral replication
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5783599A (en) * 1993-02-24 1998-07-21 Octamer Inc Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones
DZ1781A1 (fr) 1993-05-21 2002-02-17 Radopah Ltd Agents d'arylation.
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US6008250A (en) 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
US5837729A (en) 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
RU2103260C1 (ru) * 1996-04-26 1998-01-27 Государственный научный центр Российской Федерации "НИОПИК" Способ получения 4-нитробензамида
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
EP1003498A4 (en) * 1997-03-26 2004-07-14 Biosource Tech Inc DI-ARYL ETHERS AND DERIVATIVES THEREOF AS ANTI-CANCER AGENTS
US5908861A (en) 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6426415B1 (en) * 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6235748B1 (en) * 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US5922775A (en) 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
CO5070700A1 (es) 1998-06-05 2001-08-28 Basf Ag Genes novedosos de (adp-ribosa) polimerasa
CZ20011546A3 (cs) 1998-11-03 2001-08-15 Basf Aktiengesellschaft Derivát substituovaného 2-fenylbenzimidazolu, způsob jeho přípravy a jeho použití
DK1133477T3 (da) 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
JP3552934B2 (ja) 1998-12-24 2004-08-11 セントラル硝子株式会社 安息香酸アミド類の製造方法
US6326517B1 (en) 1998-12-10 2001-12-04 Central Glass Company, Limited Method of producing benzamides
US6201020B1 (en) * 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) * 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
AP1538A (en) 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
KR20010101675A (ko) * 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
US6423696B1 (en) * 1999-04-16 2002-07-23 The United States Of America, As Represented By The Department Of Health & Human Services Inhibition of arylamine N-acetyl transferase
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6277990B1 (en) 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
AU2001264595A1 (en) * 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20040053888A1 (en) 2001-01-04 2004-03-18 Norio Suzuki Cyclodextrin-containing pharmaceutical preparation
US20020164633A1 (en) 2001-04-20 2002-11-07 Inotek Pharmaceuticals Corporation Cell-based assay for detecting activation of poly (ADP-ribose) polymerase
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US6924284B2 (en) 2001-08-15 2005-08-02 Icos Corporation PARP inhibitors
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2003080077A1 (fr) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Utilisation combinee de derives anticancereux de l'indolopyrrolocarbazole et d'un autre agent anticancereux
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
CA2505520C (en) 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
JP2007535895A (ja) * 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
MXPA05012812A (es) * 2003-05-28 2006-02-28 Guilford Pharm Inc Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
US20050004038A1 (en) * 2003-06-27 2005-01-06 Lyon Robert P. Bivalent inhibitors of Glutathione-S-Transferases
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
RU2006106267A (ru) * 2003-08-01 2006-07-27 Уайт Холдингз Корпорейшн (Us) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
CN1870991A (zh) * 2003-09-04 2006-11-29 安万特药物公司 作为多聚(adp－核糖)聚合酶(parp)抑制剂的被取代的吲哚类化合物
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
MXPA06005686A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
NZ547193A (en) 2003-12-05 2010-03-26 Janssen Pharmaceutica Nv 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
UA91007C2 (ru) 2003-12-10 2010-06-25 Янссен Фармацевтика Н.В. Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
US7680864B2 (en) 2004-03-02 2010-03-16 Intel Corporation Method and apparatus for managing access to stored objects based on retention policy
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2005336083A (ja) 2004-05-26 2005-12-08 Sumitomo Chemical Co Ltd 芳香族アミノ化合物の製造方法
US7803795B2 (en) 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
UA86237C2 (uk) 2004-06-30 2009-04-10 Янссен Фармацевтика Н.В. Похідні заміщеного 2-алкілхіназолінону як інгібітори parp
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
US20060035890A1 (en) 2004-08-10 2006-02-16 Amit Banerjee Compounds and methods for the treatment of ubiquitin conjugating disorders
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
RU2361592C2 (ru) * 2004-09-22 2009-07-20 Пфайзер Инк. Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
ATE551345T1 (de) * 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
EP1828165B1 (en) 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
CN1768732A (zh) 2004-11-02 2006-05-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗肿瘤药物中的应用
CN1768733A (zh) 2004-11-02 2006-05-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗艾滋病药物中的应用
US20070157330A1 (en) * 2004-12-07 2007-07-05 Min Wu Reconstituted human breast tumor model
GB0428111D0 (en) 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
EP1904468A4 (en) * 2005-06-10 2009-04-22 Bipar Sciences Inc PARP MODULATORS AND TREATMENT OF CANCER
CA2615374A1 (en) 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2007041357A1 (en) * 2005-09-29 2007-04-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
US20080293795A1 (en) 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
RS53082B (en) 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. COMBINED THERAPY WITH PARP INHIBITORS
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
JP4611441B2 (ja) * 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US20070292883A1 (en) 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
DE102006037399A1 (de) * 2006-08-10 2008-02-14 Archimica Gmbh Verfahren zur Herstellung von Arylaminen
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
CN101190211B (zh) 2006-11-23 2011-08-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗病毒性肝炎药物中的应用
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
GB2447796C (en) 2007-01-16 2009-11-12 Bipar Sciences Inc Iodonitrobenzamide formulations for cancer and viral diseases.
EP2134691B1 (en) 2007-03-08 2012-01-25 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp and tank inhibitors
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症

Also Published As

Publication number Publication date
CR11485A (es) 2010-09-13
NI201000083A (es) 2011-04-27
WO2009064738A2 (en) 2009-05-22
CN101917982B (zh) 2013-03-20
DOP2010000141A (es) 2010-07-31
CA2705537A1 (en) 2009-05-22
AU2008321128A1 (en) 2009-05-22
CO6290650A2 (es) 2011-06-20
US7732491B2 (en) 2010-06-08
RU2480211C2 (ru) 2013-04-27
TW200924739A (en) 2009-06-16
NZ586125A (en) 2012-12-21
SG185952A1 (en) 2012-12-28
ECSP10010240A (es) 2010-07-30
AR069291A1 (es) 2010-01-13
RU2010123884A (ru) 2011-12-20
CN101917982A (zh) 2010-12-15
EP2217227B1 (en) 2013-08-21
MX2010005222A (es) 2010-09-28
TW201249430A (en) 2012-12-16
MA31909B1 (fr) 2010-12-01
IL205689A0 (en) 2010-11-30
US20120269861A1 (en) 2012-10-25
TN2010000208A1 (en) 2011-11-11
RU2012153963A (ru) 2014-06-20
EP2217227A2 (en) 2010-08-18
EP2217227A4 (en) 2011-06-08
KR20100102609A (ko) 2010-09-24
DOP2012000291A (es) 2013-04-15
US20100003192A1 (en) 2010-01-07
WO2009064738A9 (en) 2009-07-16
JP2011503111A (ja) 2011-01-27
US20090131529A1 (en) 2009-05-21
CN103169973A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
GT201000140A (es) Tratamiento de cáncer de mama con un inhibidor de parp solo o en combinación con agentes anti-tumorales.
ECSP10010235A (es) Tratamiento de cáncer de útero y cáncer de ovario con un inhibidor de parp solo o en combinación con agentes antitumorales
AR108615A2 (es) Terapia adyuvante con herceptin®
MX344522B (es) Agentes de union a cd33.
CR20110580A (es) Compuestos vinil indazolilo
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2010008817A (es) Tratamiento de cancer de prostata en etapa metastatica con degarelix.
CY1117722T1 (el) Βελτιωμενη αγωγη του πολλαπλου μυελωματος
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
AR057941A1 (es) Agentes terapeuticos para el cancer de prostata
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
MX342250B (es) Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
CR20110341A (es) Compuesto amino pirazol
MX358254B (es) Métodos para el tratamiento de cáncer de mama.
BR112012011457A2 (pt) uso antitumoral de cabazitaxel.
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
ECSP099574A (es) Agonistas adrenoreceptores alfa2c
EA201590650A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
DOP2011000282A (es) Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
CL2015002454A1 (es) Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos.
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
CU20100113A7 (es) Péptido para la terapia del cáncer
UA100869C2 (ru) Лечение рака яичника с помощью соединения йодонитробензамида в комбинации с противоопухолевыми средствами